(Q40404207)

20 September 2017

title

Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis (English)

1 reference

20 September 2017

0 references

Gang-Jun Du

1

1 reference

20 September 2017

Hai-Hong Lin

series ordinal

2

1 reference

20 September 2017

Qi-Tai Xu

series ordinal

3

1 reference

20 September 2017

Min-Wei Wang

series ordinal

4

1 reference

20 September 2017

publication date

1 August 2005

1 reference

20 September 2017

published in

Vascular Pharmacology

1 reference

20 September 2017

volume

43

1 reference

20 September 2017

issue

2

1 reference

20 September 2017

page(s)

112-119

1 reference

Cyclooxygenase-2: a novel target for cancer chemotherapy?

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.04.003

Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.04.003

Effect of thalidomide on growth and metastasis of canine osteosarcoma cells after xenotransplantation in athymic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.04.003

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.04.003

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.04.003

Thalidomid: current role in the treatment of non-plasma cell malignancies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.04.003

Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.04.003

Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.04.003

Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.04.003

Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.04.003

Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.04.003

Thalidomide: tragic past and promising future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.04.003

Thalidomide in multiple myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.04.003

Thalidomide: emerging role in cancer medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.04.003

Response to thalidomide in multiple myeloma: impact of angiogenic factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.04.003

7 January 2021

Thalidomide in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.04.003

Thalidomide and its analogues as cyclooxygenase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.04.003

Bax:Bcl-2 ratio modulation by bryostatin 1 and novel antitubulin agents is important for susceptibility to drug induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line, Reh.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.04.003

10.1016/J.VPH.2005.04.003

7 January 2021

Identifiers

DOI

1 reference

20 September 2017

1 reference